https://www.science.org/content/article/co-developer-cassava-s-potential-alzheimer-s-drug-cited-egregious-misconduct Cassava Sciences, a biotech company whose work on the experimental Alzheimer’s drug simufilam has been heavily criticized and is the subject of ongoing federal probes, has suffered another blow. A much-anticipated investigation by the City University of New York has accused neuroscientist Hoau-Yan Wang, a CUNY faculty member and longtime Cassava collaborator, of scientific misconduct involving 20 research papers. Many provided key support for simufilam’s jump from the lab into ongoing clinical trials.
…The 50-page report obtained by Science says the scientist failed to turn over to the panel “even a single datum or notebook in response to any allegation” and cites “Wang’s inability or unwillingness to provide primary research materials to this investigation” as a “deep source of frustration.”
----------- At least AMRN's and Dr Bhatts work is well documented and freely available
News 
Market Data 
Discover 
AI
